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Chronic painTo test our hypothesis that testosterone deﬁciency plays an important role in chronic pain, a Phase I/II pilot study
was initiated with 12 ﬁbromyalgia patients to verify that a daily dose for 28 days with transdermal testosterone
gel would 1) signiﬁcantly and safely increase mean serum testosterone concentrations from low baseline levels
to mid/high-normal levels, and 2) effectively treat the pain and fatigue symptoms of ﬁbromyalgia. Pharmacoki-
netic data conﬁrmed that serum free testosterone concentrationswere raised signiﬁcantly above baseline levels,
by assessment ofmaximumhormone concentration (Cmax) and area under the curve (AUC) parameters: free tes-
tosterone Cmax was signiﬁcantly raised from amean of 2.64 pg/mL to 3.91 pg/mL (p b 0.05), and 24 hour free tes-
tosterone AUC was signiﬁcantly raised from a mean of 35.0 pg-hr/mL to 53.89 pg-hr/mL. Assessment of the
typical symptoms of ﬁbromyalgia by patient questionnaire and tender point exam demonstrated signiﬁcant
change in: decreased muscle pain, stiffness, and fatigue, and increased libido during study treatment. These re-
sults are consistent with the hypothesized ability of testosterone to relieve the symptoms of ﬁbromyalgia. Symp-
toms not tightly related to ﬁbromyalgia were not improved.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Although ﬁbromyalgia can strike at an early age, the mean age of
onset in women has been reported as 44–53 years [1–3], similar to
the mean age for menopause, 51 years [4]. Fibromyalgia affectspartate aminotransferase; AUC,
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. This is an open access article under3.4% of women and 0.5% of men [5] or 2–4% of the population [6].
The incidence among women aged 50–80 is even higher at 6–7%
[6]. Although criteria for diagnosing ﬁbromyalgia in the clinic are
well deﬁned [7–9], the condition remains difﬁcult to treat. The obvi-
ous therapeutic approaches for ﬁbromyalgia or chronic pain all have
risks: First, non-steroidal anti-inﬂammatory drug analgesics
(NSAIDS), when used on an on-going basis for chronic conditions,
can cause signiﬁcant GI tract irritation. Secondly, the morphine-
related opioid analgesic class of drugs such as oxycodone and
hydromorphone can cause hyperalgesia [10], addiction, testosterone
deﬁciency [11], and a lack of efﬁcacy or “tolerance” develops over
time, in which the morphine antinociceptive dose–response curve
is displaced to the right [12]. Opioids are not recommended for peo-
ple with ﬁbromyalgia for these reasons. Third, the anti-depressants
can have side effects that include sexual dysfunction and decreased
libido [13]. Current practices for treatment also include non-
pharmacologic therapies such as exercise, cognitive behavioral ther-
apy, alternative medicine therapies and CNS neurostimulatory ther-
apies [7,14]. All these approaches are less than optimal for providing
relief either because of their well-recognized signiﬁcant risks and/or
suboptimal efﬁcacy. Here we use ﬁbromyalgia as an FDA preferredthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Patient demographics.
Pat ID# Age Ht (in) Wt (lb) BMI
001 54 66 155 25.1
002 54 62 139 25.9
005 51 64 150 26.0
006 53 60 130 25.5
007 54 62 160 29.3
009 53 67 160 25.1
010 45 67 175 27.5
011 50 62 135 24.8
012 54 62 122 22.4
016 55 64 140 24.3
017 45 62 140 25.7
018 42 64 130 22.4
Mean 51 63 145 25.3
Median 53 63 140 25.3
Minimum 42 60 122 22.4
Maximum 55 67 175 29.3
250 H.D. White et al. / International Immunopharmacology 27 (2015) 249–256model for the study of chronic pain [15] in recognition of the need for
more targeted therapeutics. Due to a large body of evidence that
links testosterone to pain, as detailed in a companion Commentary
in this issue, it was hypothesized that testosterone therapy in these
patients would signiﬁcantly and effectively reduce pain without
the side effects of the above commonly used therapeutics. Further,
the side effects of androgen excess can be avoidedwhen testosterone
is delivered safely such that serum levels of bioavailable or free tes-
tosterone are within the reference range of the test used for
detection.
In the phase I/II pilot study described here, we tested a novel hy-
pothesis, that muscle pain and chronic fatigue, primary symptoms in
women with ﬁbromyalgia [7–9], are caused by testosterone deﬁciency,
and that testosterone therapy can be safely delivered and it can signiﬁ-
cantly dampen chronic pain without the well known side effects of opi-
oids, anti-depressants, NSAIDS or benzodiazepines, all of which have
been prescribed for ﬁbromyalgia.
The American College of Rheumatology diagnostic criteria for ﬁ-
bromyalgia [7–9] were used as a set of parameters for tracking the
efﬁcacy of testosterone replacement therapy in dampening pain in
these patients. Fibromyalgia patients treated transdermally with a
testosterone gel formulation once a day (8:00 AM) for 28 days
responded well with respect to raising both free testosterone and
total testosterone serum levels signiﬁcantly and safely above base-
line. In addition, clinical symptoms of muscle pain, stiffness and
fatigue were signiﬁcantly decreased, libido was signiﬁcantly in-
creased, and symptoms not tightly associated with ﬁbromyalgia
failed to show a response.
2. Patients, materials and methods
2.1. Patient selection
Women were recruited by advertising, and all study protocols were
approved by the institutional review board. Subjects were aged 40–55
and diagnosed with ﬁbromyalgia using the American College of Rheu-
matology criteria [7–9]. See Table 1 for an overview of patient selection
criteria, and Table 2 for demographics. Women were included if they
agreed to keep their medicines unchanged during the study, except
for analgesics which were permitted to be decreased. Women who
had been taking hormone replacement therapy were enrolled if theyTable 1 Patient selection criteria.
Primary screening:
Sex, age Female, 40–55
Diagnosis ACR criteria for ﬁbromyalgia
Exclusion criteria Pregnant, on hormone therapy, undiagnosed vaginal
bleeding, BMI N 30, ethanol or illicit drug abuse, active
thrombophlebitis, breast cancer, hypertension, major
skin disease, acne, hirsutism
Secondary screening:
Cardiac exclusion
criteria
Total fasting cholesterol N 240 mg/dL, HDL b 35 mg/dL,
LDL N 210 mg/dL, triglycerides N 300 mg/L
Hepatic function
exclusion criteria
ALT N 1.5 × N (normal at 0–40 U/L), alkaline phosphatase
N 2 × N (normal at 40–120 U/L), AST N 1.5 × N (normal at
10–30 U/L), serum albumin N N (normal at 3.2–5.2 g/dL),
total bilirubin N N (normal at 0.2–1.3 mg/dL), direct
bilirubin N N (conjugated, soluble; normal at
0.0–0.3 mg/dL)
Kidney function
exclusion criteria
BUN N 2 × N (normal at 8–18 mg/dL), serum creatinine N
N (normal at 0.7–1.2 mg/dL)
Hematologic function Normal CBC, normal hemoglobin (12–16 g/dL)
Additional serum tests Total testosterone in the lower half of the reference range
(excluded if N0.4 ng/mL); an FSH b22 IU/L indicated pre-
or peri-menopausal status and thus the
need for adequate contraception during therapy
Diet Patient must agree to stop taking St. John's wort (induces
catabolism of hormones by activating liver CYP3A)were off hormone therapy at least 2 weeks prior to, and for the duration
of, the study. Pre- or peri-menopausal women were required to have
adequate alternative contraception and a negative pregnancy test.
Treatment was started within the early follicular (proliferative) phase
of the cycle. Patients were included if they were willing to exercise
20 min a day, 5 days per week during therapy to promote the effects
of testosterone, a requirement requested by the local Institutional Re-
view Board despite the common understanding that exercise is difﬁcult
for individuals with ﬁbromyalgia. A placebo-controlled studywill be re-
quired to better evaluate the relative importance of testosterone vs
exercise.
2.2. Screening by patient preliminary questionnaire
Pregnant women and women on hormone therapy, hormone con-
traceptives or infertility drugs were excluded. Women were excluded
from the study if they reported undiagnosed vaginal bleeding, had a
body mass index BMI N 30, admitted to ethanol or illicit drug abuse,
had active thrombophlebitis, breast cancer, hypertension (BP N 160
systolic/95 diastolic with or without medication, after sitting for
5 min), or major skin disease, acne or hirsutism. Prior to serum testing,
the most frequent exclusion criterion was for BMI N30.
2.3. Secondary screening. Sex steroid hormone status
The American Society for Reproductive Medicine's Princeton Con-
sensus statement on female androgen insufﬁciency recommended ther-
apy for women with serum free testosterone concentrations in the
lowest quartile of the normal premenopausal range [16]. Since sufﬁcient
numbers of womenwith deﬁciency will skew the bottom of any test kit
reference range downward, the study here enrolled womenwhose pre-
liminary test demonstrated levels for total testosterone in the lower half
of the reference range (16 of 18ﬁbromyalgia patientswhowere initially
evaluated, see Section 2). Adequate estrogen status has also been rec-
ommended to be provided by the Princeton consensus statement
panel, although, after the WHI studies [17,18], estrogen/progestin hor-
mone replacement therapy remains a topic of discussion within the
clinic and it was not evaluated here.
2.4. Physical exam and blood tests
Prior to enrollment, physical examination was performed and
overnight fasting patient blood was collected and tested for cardio-
vascular risk factors (lipid levels), hepatic function, kidney function,
hematologic function, FSH and total testosterone (details in Table 1).
Blood was collected at 8:00 a.m., the zenith of the circadian cycle of
circulating androgens [19]. Patients were cycled so that day 1 of
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Fig. 1. Serum total testosterone concentrations in ﬁbromyalgia patients are increased and
normalized in response to testosterone gel therapy. Blood was taken by venipuncture
from twelve ﬁbromyalgia patients who ﬁt the eligibility requirements, on day 1 at the
times indicated and then again on day 28 of therapy (24 hr time scale on the horizontal
axis; for each 24 hr proﬁle, serum sampling started at 8:00 AM and ended the next day
at 8:00 AM). Low and high ends of the reference range are as indicated by the dashed hor-
izontal lines, and as speciﬁed inSection 2: low end, 0.1 ng/mL; high end for age 40–60 (this
study), 0.90 ng/mL; high end for age 30–40, 2.20 ng/mL. Means ± SEM for day 1 (open
symbols) vs day 28 (ﬁlled symbols). 95% CI (conﬁdence interval) analysis demonstrated
statistical signiﬁcance for these data.
251H.D. White et al. / International Immunopharmacology 27 (2015) 249–256therapy was within the early proliferative phase of the 28 day cycle
for premenopausal patients. Both total and free testosterone levels
are known to peak just before the pre-ovulatory LH surge in normal
premenopausal women [20]. Patients were excluded for serum total
testosterone N0.4 ng/mL (the upper half of the reference range). Pa-
tients with FSH b22 IU/L (premenopausal status) were required to
use non-hormonal contraception. Patients who had undergone bilat-
eral oophorectomy were not tested for FSH and were not required to
have adequate contraception. Patients were required to stop taking
St. John's wort, since St. John's wort is known to induce catabolism
of sex steroid hormones by activating CYP3A, a detoxifying enzyme
complex in the liver [21,22]. Physical exam and blood tests were re-
peated at the end of the study to assess whether testosterone thera-
py adversely affected the general health of the study patient.
2.5. Study protocol
The study protocol was approved by the Dartmouth College Com-
mittee for Protection of Human Subjects. Written informed consent
was obtained from study subjects prior to entry into the study, and
the consent processwas ongoing throughout the study. An independent
Data Safety Monitoring board was in place. Twelve patients who met
the eligibility criteria above were scheduled for physical exams includ-
ing tender point assessment [9], veriﬁcation of ﬁbromyalgia diagnosis
[7–9], and assessment of general health. On day 1, blood was drawn
by venipuncture at 0, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h for 24 hr pharmaco-
kinetic proﬁling of testosterone serum concentrations. Testosterone gel,
0.75 g 1%w/w (0.75mg bioavailable, see below), was applied by the pa-
tients to their lower abdominal skin just after the zero time point blood
draw (8:00 a.m.). The patient also ﬁlled out a pain assessment question-
naire form (see pain assessment, below) and was given packets of tes-
tosterone gel for 8:00 a.m. daily application to lower abdominal skin,
instructions for use and a patient medication log and exercise log for
28 days of therapy. On day 28, the blood draws for 24 hr pharmacoki-
neticmeasurementswere repeated, and a follow-up examwas repeated
at the end of the 28 days of therapy.
2.6. Formulation of testosterone gel and guidance for treatment
The gel used for this study was a 1% w/w testosterone gel, USP
grade. The daily gel dose applied to the lower abdominal skin was
0.75 g of the 1% w/w testosterone gel; an expected bioavailability
of 10%would deliver 0.75 mg testosterone over 24 h. The gel was for-
mulated with women in mind by Bentley Pharmaceuticals, Inc.
(North Hampton, NH; subsequently CPEX Pharmaceuticals, Inc.)
using GLP conditions, and was colorless, comfortable on the skin
with no irritation, quick drying and non-staining. The gel was pro-
duced at Bentley Pharmaceuticals under DEA license. Testosterone
is a Schedule C-III controlled substance (Anabolic Steroid Control
Act). Thus, all testosterone treatment samples were itemized, and
accounted for at the end of the study.
The American Society for Reproductive Medicine's Princeton Con-
sensus Statement on female androgen insufﬁciency has recommended
treating women only if clinical symptoms such as diminished sense of
well-being and chronic fatigue are clearly present [16]. The North
American Menopause Society has also weighed in on this topic,
recommending treatment for clinical symptoms of deﬁciency such as
decreased sexual desire while monitoring blood levels to avoid
supraphysiologic levels [23]. Most recently, the Endocrine Society eval-
uated androgen therapy for women, providing a clinical practice guide-
line [24]. Androgen therapy in healthy women was advised against,
however deﬁciency symptoms of chronic pain were not considered. It
was recommended that any woman who did receive testosterone ther-
apy bemonitored for signs and symptoms of androgen excess, a recom-
mendation that was adhered to here.2.7. Testosterone serum concentrations
Testosterone concentrations were determined by enzyme linked
immunoassay (DSL-10-4900 Active Free Testosterone EIA; DSL-10-
4000 Active [Total] Testosterone EIA; Diagnostic Systems Laboratories
or DSL, Inc.,Webster, Texas), where serum testosterone from study sub-
jects competed with enzyme-linked testosterone bound to anti-
testosterone mAb. This assay system was selected based on its ability
to detect the lower concentrations of testosterone found in women as
well as concentrations in the upper ranges. Free testosterone concentra-
tions were determined by EIA using an anti-testosterone antibody that
recognizes the unbound testosterone in the test sample, and has low af-
ﬁnity for sex hormone binding globulin and albumin.
Upper and lower limits for the DSL testosterone assay reference
ranges are indicated by the dashed horizontal lines in Figs. 1 and 2,
and are deﬁned as follows: total testosterone for women aged 30–40
(generally premenopausal), 0.1–2.20 ng/mL, mean 0.50 ng/mL, StDev
0.54 ng/mL (n = 16); total testosterone for women aged 40–50 (this
study, generally pre–peri–postmenopausal), 0.1–0.9 ng/mL, mean
0.31 ng/mL, StDev 0.23 ng/mL (n = 15); total testosterone for women
aged 50–60 (this study, generally peri–postmenopausal), 0.1–
0.69 ng/mL, mean 0.27 ng/mL, StDev 0.19 ng/mL (n = 16); free testos-
terone for premenopausal women 0.33–3.29 pg/mL, mean 1.42 pg/mL,
StDev 0.09–0.22 pg/mL, (n = 38); and free testosterone for postmeno-
pausal women 0.56–1.86 pg/mL, mean 1.28 pg/mL, St Dev 0.09–
0.22 pg/mL, (n = 12). Total testosterone sensitivity was 0.04 ng/mL
(n=20); free testosterone sensitivity was 0.16 pg/mL (n=20). Percent
cross-reactivity for total testosterone was: testosterone 100%, 5-alpha-
dihydrotestosterone 6.6%, and androstenedione 0.9%, all other steroids
tested b2.2%. Percent cross-reactivity for free testosterone was: free
testosterone 100%, 5-alpha-dihydrotestosterone not detectable, andro-
stenedione 0.006%, all other steroids tested b0.3%.
For the purposes of determining mean testosterone concentra-
tions, times were based on the nearest hour. Of the 240 time points
taken for the pharmacokinetic data (10 time points per individual × 2
2 sets per individual × 12 individuals), 1 time point was missed
(#012, 4 h point) and 3 additional time points were in-between the
standard times for taking blood (#010, 8 h point; #012, 4 h and
10 h points). Values for these time points were derived by interpola-
tion for the purposes of deriving mean testosterone concentrations.
01
2
3
4
5
6:
00
8:
00
10
:0
0
12
:0
0
14
:0
0
16
:0
0
18
:0
0
20
:0
0
22
:0
0
0:
00
2:
00
4:
00
6:
00
8:
00
FT
 (p
g/m
L)
TIME OF DAY
Free Testosterone 
d1(circles), d28(squares) Mean ± SE, n=10
premenopausal
postmenopausal
low end of ref range
Testosterone
Fig. 2. Serum free testosterone concentrations in ﬁbromyalgia patients are increased and
normalized in response to testosterone gel therapy. Serum free testosterone concentra-
tions were quantitated using methodology similar to Fig. 1. The low end of the reference
range for pre- and post-menopausal women is 0.33 pg/mL, represented by the lower
dashed horizontal line. The high end of the reference range for premenopausal women
is 3.3 pg/mL, represented by the upper dashed horizontal line; and the high end for post-
menopausal women is 1.9 pg/mL, represented by the middle dashed horizontal line.
Means ± SEM for day 1 (open symbols) vs day 28 (ﬁlled symbols). 95% CI analysis dem-
onstrated statistical signiﬁcance for these data.
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Fig. 3. All typical symptoms of ﬁbromyalgia were improved in ﬁbromyalgia patients after
testosterone gel therapy. Patients were administered a Patient Questionnaire Form by the
study coordinator to assess their feelings of pain. For the categories of muscle pain, stiff-
ness, fatigue upon awakening and tiredness, the number 10 represents the worst severity
of symptoms (decreases expected in response to therapy), with the exceptions that head-
ache frequency was measured on a scale of 1–4, and “sleeplessness” was a “fatigue upon
awakening” background information parameter for the number of hours of sleep each in-
dividual thought was optimal for themselves. For libido, the number 10 represents the
strongest feelings of libido (sex drive; increases expected in response to therapy). Day 1,
dark bars. Day 28, hatched bars. A, parameters that are highly prevalent in the ﬁbromyal-
gia patient population [29]; B, parameters of headache, depression and anxiety are more
weakly prevalent in the ﬁbromyalgia patient population. Panel A, P valueswere statistical-
ly signiﬁcant for all parameters, p b 0.05. Panel B, P values demonstrate lack of statistical
signiﬁcance for all parameters, p N 0.05.
252 H.D. White et al. / International Immunopharmacology 27 (2015) 249–256A noncompartmental pharmacokinetic analysis usingWinNonlin Pro
(Pharsight, Mountain View, California) used the exact time points re-
corded for all the patients.
Two subjects (#010 and #016) tested abnormally and unrealisti-
cally high for free testosterone, well above the reference range for
women, likely due to interference with the EIA antibody by some
unknown serum factor present in those individuals. Justiﬁcation
for exclusion of those data in Fig. 2 and Table 4, provided in
Section 3.2, includes the fact that those individuals had normal
total testosterone levels and did not have any clinical signs of
hyper-androgenization such as hirsutism which they would have
had if their free testosterone levels had actually been that high. Be-
cause those data points were excluded from Fig. 2, the data are pro-
vided here: For day 1/day 28, subject #010: 0 h, 5.25/7.75 pg/mL;
1 h, 4.48/6.32 pg/mL; 2 h, 6.86/6.47 pg/mL; 3 h, 5.52/5.99 pg/mL;
4 h, 3.40/6.60 pg/mL; 6 h, 3.85/7.14 pg/mL; 8 h, 4.19/6.46 pg/mL;
10 h, 3.75/6.00 pg/mL; 12 h, 4.93/6.48 pg/mL; and 24 h, 6.65/
10.88 pg/mL. For day 1/day 28, subject #016: 0 h, 6.45/7.08 pg/mL;
1 h, 6.60/5.77 pg/mL; 2 h, 4.77/6.83 pg/mL; 3 h, 4.46/5.98 pg/mL;
4 h, 6.39/8.649 pg/mL; 6 h, 6.32/7.44 pg/mL; 8 h, 5.05/6.41 pg/mL;
10 h, 3.77/7.01 pg/mL; 12 h, 7.49/4.73 pg/mL; and 24 h, 6.98/
9.63 pg/mL. Test reagents were extensively controlled by positive
and negative controls, comparison assays, intra-assay and inter-
assay controls, etc. to ensure all other testosterone EIA testing per-
formed as expected.
2.8. Pain assessment
Patients were administered questionnaire forms on day 1 and
again at the end of therapy on day 28 to assess pain and the other
symptoms of ﬁbromyalgia over the past week. The patient question-
naire was based on a published and validated Fibromyalgia Impact
Questionnaire as well as other accepted criteria for ﬁbromyalgia pa-
tient assessment [9,25,26] and included the following parameters:
muscle pain, stiffness, fatigue upon awakening, tiredness, libido, de-
pression and anxiety. A verbally anchored 100 mm visual analog
scale was used (VAS, denoted as 0–10 in Fig. 3, and see Results for
verbal anchors used). Tender point exams were administered by a
qualiﬁed rheumatologist experienced in treating women with ﬁbro-
myalgia, and involved applying approximately 9 lb (4 Kg) of pressure
at each tender point, asking whether the patient felt pain, andscoring pain on a 10 point scale with verbal anchors of “no pain”
and “severe pain”, data in Fig. 4. This practice was in accordance
with criteria speciﬁed by the American College of Rheumatology.
Exams were administered just prior to Day 1 of therapy (and there-
fore designated as “pretreatment”) and at the end of therapy. The
pretreatment tender point assessment was performed on all patients
within 1 week before the start of therapy. Dolorimeter readings were
taken from the bilateral second costochondral junction and trapezius
tender points, for comparison, in 11 of the 12 study subjects, and the
resultant data supported the non-dolorimetry tender point exam re-
sults (dolorimetry data not shown).2.9. Statistical analysis
Pharmacokinetic analysis of serum testosterone concentration vs
time data was carried out using WinNonlin Pro software using the
noncompartmental model with extravascular input. Differences be-
tween Day 1 and Day 28 Cmax and AUC were assessed by calculating
individual subject Day 28 minus Day 1 data and estimating 95% con-
ﬁdence intervals of this difference to determine if signiﬁcance
(p b 0.05) was reached. Tender point evaluations were analyzed by
Student's t test (paired, 2-tailed) after summing all 18 tender point
values for each individual at baseline vs d28 (end of study).
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Tender Point
TENDER POINT EVALUATION -- Pretreatment vs Day 28
(P=0.012 for sum of tender points on Day 28 vs Day 1)
Fig. 4. Tender point painwas decreased inﬁbromyalgia patients after testosterone gel therapy. Tender point examswere administered by the study rheumatologist. Painwas assessed on a
visual analog scale VAS of 0–10, with zero being no pain, and 10 being the most pain. Means of scores ± SEM are shown. The p value, determined by summing all tender point values for
each patient at the baseline vs d28 time points and assessing by paired Student's t test, was p= 0.012. Dark bars, pretreatment (PT). Hatched bars, Day 28. R, right side tender point; L, left
side tender point.
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3.1. Serum total testosterone concentrations were signiﬁcantly increased in
ﬁbromyalgia patients in response to treatment with testosterone gel
hormone replacement therapy
Twelve ﬁbromyalgia patients 40–55 years of age whomet the study
eligibility criteria (Table 1, Section 2) were enrolled for this study and
treated. Patient demographics for age, height and weight are shown in
Table 2. All patients were white Caucasian females, reﬂective of demo-
graphics in northern New England. Serum total testosterone concentra-
tions vs time data for Day 1 and Day 28 are shown in Fig. 1. Reference
ranges for the concentration of total testosterone in serum from
women 40–50 years of age and 50–60 years of age are provided in
Section 2, and denoted by dashed horizontal lines in Fig. 1. The day 1
zero time point for total testosterone conﬁrmed that these patients ini-
tially had total testosterone concentrations in the lower half of the ref-
erence range. The mean serum concentration of total testosterone
24 h after application of the ﬁrst dose of hormone on Day 1 was signif-
icantly higher than themean serum concentration for time zero on Day
1 (Fig. 1, p = 0.01). Steady state serum concentrations were reached
quickly in the aggregate by 24 h on day 1, as conﬁrmed on day 28 via
similar mean concentrations at both the beginning and end of theTable 3
Total testosterone pharmacokinetic parameters.
Total testosterone d1 (n = 12) Total testostero
Tmax Cmax Cmin AUC (0–24 h) Tmax Cm
h ng/ml ng/mL ng·h/ml h ng/
Mean 1.21 0.17 18.36 1.9
SD 0.71 0.10 7.10 0.9
Median 16.11 1.08 0.18 16.88 10.17 1.7
Min 2.33 0.53 0.00 10.35 1.62 0.6
Max 24.75 3.05 0.37 30.95 23.92 3.124 h sampling. Upon treatment, mean total testosterone values were
raised to just above the reference range for women aged 40–60
(42–55 was the age range for this study). All values for day 1 or day
28, however, were well below the premenopausal reference range for
women aged 30–40, and also well below the upper end of the total tes-
tosterone reference range formen (5–10 ng/mL, using the sameDSL test
kit). Furthermore, it is the free testosterone serum levels (see Section 4)
that are important for deﬁning safe levels since free testosterone (not
total testosterone) is an appropriate biomarker for bioavailable
testosterone.
Summary pharmacokinetic parameter analysis demonstrated
signiﬁcantly increased mean total testosterone maximum concen-
tration in response to testosterone therapy: Cmax was 1.92 ng/mL
on day 28 comparedwith 1.21 ng/mL on day 1 (Table 3). Signiﬁcantly
increased mean total testosterone area under the curve values
(assessed over the 24 hr proﬁling time period) were also found:
AUC was 28.75 ng-h/mL on day 28 compared with 18.36 ng-h/mL
on day 1, p b 0.05. The differential Cmax and AUC values for day 28
after subtraction of day 1 baselines are provided in the right panel
of Table 3, with 95% CI analysis demonstrating statistical signiﬁcance
for these data. The data, taken together, demonstrate that with ther-
apy, mean serum total testosterone concentrations initially rose
quickly over the ﬁrst 3 h and were then sustained over time. Inne d28 (n = 12) d28− d1 differential
ax Cmin AUC (0–24 h) Cmax Cmin AUC (0–24 h)
ml ng/mL ng·h/ml ng/ml ng/mL ng·h/ml
2 0.72 28.75 0.7 0.55 10.38
0 0.44 13.91 0.96 0.42 12.61
9 0.61 26.71
3 0.21 11.29
3 1.67 59.56
95% CIs CI high -N 1.36 0.79 19.23
For diff CI low -N 0.06 0.31 1.55
254 H.D. White et al. / International Immunopharmacology 27 (2015) 249–256addition, mean serum total testosterone concentrations were raised
from baseline levels (day 1, 8:00 am) at the lower boundary of the
reference range to just above the upper end of the reference range
for women aged 40–60 and below the upper end of the reference
range for premenopausal women.
3.2. Low serum free testosterone concentrations were safely raised to
premenopausal concentrations in ﬁbromyalgia patients in response to
testosterone gel hormone replacement therapy, and the differences in
increased serum levels vs baseline levels were statistically signiﬁcant
Concentrations of free testosterone in serum were similarly ana-
lyzed, Fig. 2. Similar results were obtained, but with the following
particular ﬁndings. Two individuals had unrealistically high concentra-
tions of free testosterone prior to and throughout the course of therapy
despite normal total testosterone levels (#010 and #016), suggesting
serum interference with the free testosterone testing antibody in
these two cases. The only medication or supplement reported by both
study subjects #010 and #016 and not by any other subject was ginger
root; and the anti-depressant Trazodonewas taken by both individuals.
Preliminary tests in vitro suggested that ginger root appears to interfere
with the enzyme linked immunoassay for free testosterone, analogous
to the ﬁnding by others that DHEA-S [27,28] can interfere with testos-
terone immunoassays. Free testosterone data for these two outliers
were therefore dropped due to interference with the EIA, whether due
to ginger root alone or in combinationwith Trazodone, for the following
reasons: 1) extremely high levels of free testosterone were found at
baseline on day 1 at zero time (prior to therapy) for only these two sub-
jects, 2) these high free testosterone levels were not possible given the
total testosterone levels found in these same patients (consistent with
some factor interfering with the antibody used in the assay), and 3) by
the lack of hirsutism and other clinical symptoms that would have oc-
curred in these two subjects if these high baseline free testosterone
levels had been real. Individual proﬁles for the remainder of the patients
showed mean serum free testosterone concentrations that signiﬁcantly
increased from the baseline at the lower end of the postmenopausal
range to the middle-to-upper half of the premenopausal reference
range in response to therapy, and remained safely within the upper
end of the premenopausal reference range (Fig. 2).
Summary pharmacokinetic parameter analysis showed a mean free
testosterone Cmax of 3.91 pg/mL on day 28 compared with 2.64 pg/mL
on day 1, and a mean free testosterone AUC of 53.89 pg-h/mL on day
28 compared with 35.0 pg-h/mL on day 1, Table 4, with 95% CI analysis
demonstrating statistical signiﬁcance for these data. Thus, free testos-
terone Cmax and AUC were signiﬁcantly increased with therapy on day
28 compared with day 1 baseline values (day 1, zero time).
3.3. Testosterone gel therapy reduced pain in ﬁbromyalgia patients
Pain parameters were evaluated by patient questionnaire using a
visual analog scale (VAS) from 0 to 10, and with verbal anchors, alongTable 4
Free testosterone pharmacokinetic parameters.
Free testosterone d1 (n = 10) Free testosteron
Tmax Cmax Cmin AUC (0–24 h) Tmax Cm
h pg/ml pg/mL pg·h/ml h pg/
Mean 2.64 0.54 35.0 3.9
SD 1.70 0.41 18.3 1.2
Median 6.38 2.19 0.41 31.8 9.13 4.1
Min 1.92 0.95 0.09 13.7 0.00 1.8
Max 24.8 6.86 1.35 64.1 24.05 5.5with other parameters (Fig. 3A and B). Muscle pain (0 = “no muscle
pain”, 10 = “incapacitating muscle pain”), stiffness (0 = “no stiffness”,
10 = “very stiff”), fatigue upon awakening (0 = “awoke well rested”,
10 = “awoke very tired”) and tiredness (0 = “no tiredness”, 10 =
“very tired/bedridden”) were all signiﬁcantly decreased during testos-
terone treatment, Fig. 3A. Formuscle pain, a deﬁning symptom forﬁbro-
myalgia, 42% of patients had 30% or greater decrease in pain, and 33% of
patients had 50% or greater decrease in pain after 4 weeks of therapy.
Muscle pain VAS score improvement was not dependent on whether
the patient had previously had a clinical relationship with the study
rheumatologist and therefore might have wanted to please the doctor.
Libido (sex drive, 0= “lowest level”, 10= “highest level”) was also sig-
niﬁcantly increased in response to testosterone treatment. Symptoms
not tightly associated with ﬁbromyalgia failed to show any signiﬁcant
response to treatment, Fig. 3B: headache severity and frequency, sleep-
lessness, depression and anxiety. P values are provided in Fig. 3.
These ﬁndings are consistent with our hypothesis that restoration of
premenopausal serum testosterone concentrations was expected to re-
lieve symptoms that most speciﬁcally relate to testosterone deﬁciency,
for example loss of muscle function, increased fatigue and loss of sexual
desire [29]. Further, the results conﬁrm the correct dose was used, nec-
essary information for designing a placebo controlled study. Blood tests
and physical exam at the end of the study veriﬁed testosterone therapy
did not adversely affect the general health of the study patient, and no
study patient reported any adverse events that were attributable to
the treatment.
Patientswere also evaluated for tender point pain prior to the begin-
ning of therapy and at the end of therapy by a rheumatologist
(Section 2), with results shown in Fig. 4. Using a pain scale of 0 to 10,
where zero is “no pain”, 10 is “severe pain”, there were mean decreases
in pain for every tender point, with statistical signiﬁcance achieved after
summing values across all 18 tender points (p = 0.012), a ﬁnding that
compares favorably to other studies using calcium channel blocker
or SNRI therapeutics for ﬁbromyalgia patients [30–33]. Using a
dolorimeter at the same ofﬁce visit to control for the ability to accurately
apply pressure by using mechanical means, pain responses were quan-
titated for the bilateral second costochondral junction and bilateral tra-
pezius tender points. The resultant dolorimetry ﬁndings supported the
non-dolorimetry tender point data (data not shown).
4. Discussion and conclusions
4.1. Overview of ﬁndings
In the prospective study here, the hypothesis that testosterone ther-
apy can decrease pain responses is supported by the clinical data:
28 days of once-a-day therapy with 0.75 g 1% (w/w) testosterone gel
1) raised serum concentrations of total and, most importantly, free tes-
tosterone in ﬁbromyalgia patients from baseline to high-normal con-
centrations for premenopausal women, and 2) signiﬁcantly reduced
the pain and fatigue symptoms of ﬁbromyalgia patients without anye d28 (n = 10) d28− d1 differential
ax Cmin AUC (0–24 h) Cmax Cmin AUC (0–24 h)
ml pg/mL pg·h/ml pg/ml pg/mL pg·h/ml
1 1.29 53.89 1.27 0.75 18.9
3 0.54 18.71 1.71 0.72 27.1
6 1.12 51.49
1 0.71 27.95
8 2.27 90.08
95% CIs CI high 2.33 1.19 35.6
For diff CI low 0.21 0.30 2.10
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cular, hepatic, kidney or hematologic function, by patient logs and by
physical exam. Our ﬁndings of increased levels of testosterone taken to-
gether with improvements observed for clinical symptoms, including
muscle pain, stiffness, fatigue and libido, support our hypothesis that
testosterone therapy given to chronic pain patients can reduce pain,
down-modulate an inﬂamed nociceptive nervous system (as discussed
in the related Commentary in this issue) and help restore feelings of
well-being.
4.2. Delivery of testosterone with a beneﬁcial safety proﬁle
It is the free and/or bioavailable testosterone blood levels (not total
testosterone) that indicate the degree of safety because complex meta-
bolic feedback mechanisms normally ensure relatively constant levels
of free and bioavailable testosterone even though total testosterone
and SHBG levels can vary substantially depending on health status and
pharmacologic input [34]. This generally holds true evenwhen total tes-
tosterone and SHBG levels are perturbed by drugs or disorders that af-
fect steroidogenesis [34].
The unique gel formulation used here demonstrated steady state
blood levels by 24 h of day 1, and even delivery over a 24 hr proﬁle pe-
riod without spiking due to unsafe delivery of “too-much too-fast” early
in the 24 hr period, a signiﬁcant problem that gels modeled after male
formulations, the patch and injection delivery are susceptible to. Our su-
perior delivery is due, in part, to the adipose effect that this particular
transdermal gel formulation provides, and it provides a prolonged
half-life. The importance of keeping free testosterone levels stable,
without spiking, and safely within the reference range is driven home
by the morbidities found in individuals with testosterone levels abnor-
mally above the reference range, for example in women with virilizing
tumors [35], breast cancer [36], in female-to-male transgenders treated
with testosterone [37], and in East German athlete doping [38]. Cause
and effect between hyperandrogenism and cardiovascular risk factors
has been demonstrated when the hyperandrogenism was corrected
resulting in a decreased cardiovascular risk proﬁle, for example [37].
That testosterone can be delivered safely to women was suggested by
a ﬁve year study from BioSante Pharmaceuticals in postmenopausal
women with elevated cardiovascular risk and hypoactive sexual desire
disorder (HSDD) who were treated with a testosterone gel (LibiGel)
and assessed for cardiovascular and breast cancer risk [39]. The FDA ac-
cepted that study as demonstrating safety [40], although LibiGel failed
to achieve primary endpoints for efﬁcacy in HSDD patients [41].
4.3. Overall conclusion
In conclusion, patients with chronic pain states, whose baseline
blood testosterone levels are in the lower half of the reference range,
will likely be responsive to testosterone replacement therapy, clearly
supporting the rationale for conducting further studies of testosterone
replacement therapy to treat ﬁbromyalgia patients in a formal double
blind placebo-controlled clinical trial.
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